Daily Stock Analysis, AUPH, Aurinia Pharmaceuticals Inc, priceseries

Aurinia Pharmaceuticals Inc. Daily Stock Analysis
Stock Information
Open
18.75
Close
18.03
High
19.22
Low
18.00
Previous Close
18.54
Daily Price Gain
-0.51
YTD High
23.42
YTD High Date
Jan 3, 2022
YTD Low
17.85
YTD Low Date
Jan 10, 2022
YTD Price Change
-4.45
YTD Gain
-19.80%
52 Week High
33.97
52 Week High Date
Nov 3, 2021
52 Week Low
9.72
52 Week Low Date
May 11, 2021
52 Week Price Change
2.84
52 Week Gain
18.70%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
Jan 18. 2017
2.38
Feb 22. 2017
3.43
24 Trading Days
44.30%
Link
LONG
Mar 1. 2017
3.71
Mar 24. 2017
8.08
17 Trading Days
117.73%
Link
LONG
May 10. 2017
7.35
May 15. 2017
7.77
3 Trading Days
5.71%
Link
LONG
Jan 2. 2018
4.85
Jan 26. 2018
5.65
17 Trading Days
16.39%
Link
LONG
Dec 26. 2018
6.00
Jan 22. 2019
6.96
17 Trading Days
16.04%
Link
LONG
Nov 15. 2019
5.22
Jan 9. 2020
20.09
36 Trading Days
284.89%
Link
LONG
Apr 1. 2020
14.12
May 1. 2020
16.13
21 Trading Days
14.27%
Link
LONG
Jan 20. 2021
14.60
Feb 2. 2021
16.16
9 Trading Days
10.66%
Link
LONG
May 14. 2021
11.92
Jun 3. 2021
13.26
13 Trading Days
11.21%
Link
LONG
Jun 18. 2021
13.00
Jun 28. 2021
13.66
6 Trading Days
5.10%
Link
LONG
Aug 23. 2021
14.33
Sep 16. 2021
19.00
17 Trading Days
32.59%
Link
LONG
Oct 20. 2021
20.65
Nov 9. 2021
30.57
14 Trading Days
48.03%
Link
LONG
Dec 17. 2021
20.98
Jan 3. 2022
22.48
10 Trading Days
7.17%
Link
Company Information
Stock Symbol
AUPH
Exchange
NasdaqGM
Company URL
http://www.auriniapharma.com
Company Phone
250-708-4272
CEO
Richard M. Glickman
Headquarters
British Columbia
Business Address
#1203-4464 MARKHAM STREET, VICTORIA BC, CANADA V8Z 7X8
Sector
Equity
Industry Category
Drugs
Industry Group
Biotechnology
CIK
0001600620
About

Aurinia Pharmaceuticals, Inc. operates as a biopharmaceutical company. It focuses on discovering and developing immunomodulating therapeutics. The company's pipeline includes voclosporin for the treatment of lupus nephritis. Aurinia Pharmaceuticals was founded by Robert Foster, Richard Glickman and Michael Martin on June 16, 1993 and is headquartered in Victoria, Canada.

Description

Aurinia Pharmaceuticals Inc., a biopharmaceutical company, is engaged in the development of a therapeutic drug to treat autoimmune diseases in Canada. The company's lead drug includes Voclosporin, a calcineurin inhibitor for the treatment of lupus nephritis. It has a development and license agreement with 3SBio Inc. for the clinical development, registration, and commercialization of voclosporin in China; and licensing and collaboration agreement with Vifor Pharma for the treatment of lupus and various proteinuric nephrology indications. The company was formerly known as Isotechnika Pharma Inc. and changed its name to Aurinia Pharmaceuticals Inc. in October 2013. Aurinia Pharmaceuticals Inc. was founded in 1993 and is headquartered in Victoria, Canada.